Episodebeskrivelse
In this episode of Breaking Protocol, Tilda Research CEO Ram Yalamanchili sits down with Dr. Tom Mather — Chief Medical Officer of a clinical-stage biotech, early-stage venture investor, and marathoner — to unpack the real bottlenecks in drug development.From seed-stage funding to Phase III trials, Tom shares a rare perspective of clinician + operator + investor.They discuss:• Why venture capital hasn’t disappeared but is demanding de-risking• The growing gap between discovery and clinical execution• Why clinical trials remain the largest financial and operational bottleneck• How machine…
Website: podcasters.spotify.com
